Gary Proulx, MD
Radiation Oncology · Methuen, MANPI 1194798165
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,500 of the $3,687 with a category attached, or 67.8%. Icad, Inc accounts for 67.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2019 at $2,500 and has fallen 99.0% since, to $25 in 2023.
Across 22 payments — averaging $167.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Icad, Inc$3K
- Palette Life Sciences, Inc.$349
- Bayer$275
- Novocure Inc.$176
- Siemens Medical Solutions USA, Inc.$145
- Sanofi$125
- plus $117 from 5 others
Across 2 payments — averaging $9105.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Icad, Inc$18K
What the payments were for
- Consulting fees$2,50068%
- Food & beverage$1,18732%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Icad, Inc | 1 | $2,500 |
| Palette Life Sciences, Inc. | 6 | $349 |
| Bayer | 3 | $275 |
| Novocure Inc. | 4 | $176 |
| Siemens Medical Solutions USA, Inc. | 1 | $145 |
| Sanofi | 1 | $125 |
| AbbVie(2 entities) | 2 | $37 |
| Astellas Pharma US Inc | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $21 |
| Tolmar Pharmaceuticals, Inc. | 1 | $18 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axxent Controller$2,500
- VariSeed 9.0$145
- Xofigo$125
- Optune$111
How this compares
$3,687 in reported general payments places this provider in the 85th percentile of 200 radiation oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Methuen
- Peter OrioBoston$1.8M
- Paul NguyenBoston$721K
- Jason EfstathiouBoston$156K
- Jonathan SchoenfeldBoston$53K
- Martin KingBoston$37K
- Raymond MakBoston$36K
- Shannon MacdonaldBoston$33K
- Nima AghdamBoston$29K
- Rachel JimenezBoston$28K
- Andrea McKeeBurlington$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.